Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation

Technology appraisal guidance
Reference number: TA249
Published: 15 March 2012
Last updated: 02 July 2021

Atrial fibrillation - dabigatran etexilate: Bristol Myers-Squibb & Pfizer comments on the ACD

Atrial fibrillation - dabigatran etexilate: Bristol Myers-Squibb & Pfizer comments on the ACD

Atrial fibrillation - dabigatran etexilate: Bristol Myers-Squibb & Pfizer comments on the ACD
01 November 2011
(174.38 Kb 50 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 31 October 2011